The study is a randomised double-blinded trial. A group of 40 tinnitus patients with a naturally low Q10 level will be selected out of a preselected group of 160 screened out of a pre-existed database or patients which visited the ENT-consultation. The 40 patients with the lowest level will be asked to take 2 months Q10 (n=20) or the placebo (n=20). To evaluate the effect on hearing and tinnitus characteristic; audiometric test, tinnitus analysis and auditory evoked responses will be used as outcome measurements.

Inclusion Criteria:

• chronic non-pulsatile tinnitus > 3 months
• tinnitus has a clear otological cause
• age > 18 years

Exclusion Criteria:

• pulsatile tinnitus
• persons who take already Q10
• pregnancy
• cervical tinnitus
• holocranial tinnitus
• depression
• mental of neurological disorders
• history of chemotherapy
• middle ear diseases